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Introduction
• Anesthetized rats (Male Fisher 344 rats,  315 ± 15 g) with pentobarbital 
sodium (60 mg/kg ip)
• Cannulated trachea (control lung inflation) and pulmonary artery 
• Excised lungs from chest cavity and rinsed of blood 
• Lungs inflated at constant pressure (4 cm H2O) and perfused with 50 ml of 
Ringers buffer (pH 7.4) at 8 ml/min
• Perfusate oxygenated with 95% O2 and 5% CO2, and maintained at 37˚C
• 50 μCi bolus dose of H3-NNK administered to perfusate reservoir
• Perfusate samples drawn at 1, 5, 10, 15, 20, 30, 45, 60, 75, 90, 105, and 120 
minutes
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Perfusate Sample Analysis
Figure 1: Metabolic scheme of NNK4
12 ± 4 %21 ± 4 %Keto Acid
5.5 ± 1 %24 ± 3 %NNAL-N-Oxide
2 ± 0.7 %7 ± 0.5 %Diol
48.5 ± 7 %10 ± 5 %NNK-N-Oxide
14 ± 4 %3 ± 0.8 %Keto Alcohol
5 ± 1 %5 ± 2 %NNAL
4.5 ± 4 %6.5 ± 2 %NNK
< LOD*9 ± 0.5 %Hydroxy Acid
Perfusate
[% of total radioactivity]
Tissue
[% of total radioactivity]
Purpose
To validate the use of the recirculating isolated perfused lung system for 
studying the lung tissue retention of NNK and its metabolites.
#5232
Table 1: Metabolites extracted from the tissue (n=4) and perfusate (n=6) following a 
120 min perfusion with 50 μCi of 3H-NNK in an isolated lung system. The metabolites 




























Figure 2: NNK and metabolites in the tissue and perfusate 
following a 120 min perfusion with 50 μCi of 3H-NNK. The 
metabolites are expressed as the mean percent (± standard 
deviation) of total radioactivity in the sample.  
24.8 ± 8.2Terminal Elimination Half-Life (min)
0.21 ± 0.05Extraction Ratio
1.63 ± 0.4Clearance (ml/min)
Table 2: Estimated pharmacokinetic parameters for NNK in an isolated lung 
system expressed as mean ± standard deviation (n=5).  
The perfusate metabolites measured in this study are similar to 
those previously reported6. However, our ability to measure 
tissue metabolites indicates that perfusate data alone will not 
give an accurate reflection of metabolic profile and retention 
by the lung tissue. 
(S)-NNAL has been reported to be as carcinogenic as NNK and 
we hypothesize that its selective retention in the lung tissue 
may be the cause7. This study demonstrates the feasibility of 
the use of the isolated perfused lung system to evaluate 
formation and retention of NNK and NNAL metabolites in the 
lung. 
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4-(Methylnitrosamine)-1-(3-pyridyl)-1-butanone (NNK) is formed by 
nitrosation of nicotine during the smoking and curing processes of 
tobacco1. NNK is one of the most abundant and potent carcinogens found 
in cigarette smoke, and requires metabolic activation to elicit its 
carcinogenic effects2,3. NNK and its major metabolite, 4-
(methylnitrosamine)-1-(3-pyridyl)-1-butanol (NNAL), can be 
metabolized by α-hydroxylation pathways to form keto alcohol, keto
acid, hydroxy acid, and diol (Figure 1). The α-hydroxylation metabolic 
pathways of NNK and NNAL have been shown to result in the formation 
of DNA adducts.  However, NNK and NNAL can also be metabolized to 
their respective N-oxide metabolites, which are considered detoxification 
pathways for the elimination of NNK and NNAL3.
NNK induces pulmonary tumors in rodents regardless of the route of 
administration3. Doses as low as 8.7 μmol/kg have been shown to induce 
lung tumors, whereas doses of 3 mmol/kg or higher are required to induce 
the formation of liver tumors5. Thus it appears that the lung tissue is 
selectively sensitive to the carcinogenic effects of NNK. It has been 
previously reported that the liver clearance (6.9 ± 1.6 ml/min) of NNK is 
greater than lung clearance (2.1 ± 0.5 ml/min) in rats, and each organ 
produces a different metabolic profile6. Since in vivo studies of 
investigating the carcinogenicity effects of NNK on the lung are
complicated by liver metabolism, it would be of interest to use the 
isolated lung perfusion system to investigate NNK metabolism and the 
retention of its metabolites in the lung. 
